BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Next Safety, Inc. Announces Bid Date for the Sale of the Company's Platform for the Pulmonary Delivery of Albuterol and the Components of Advair(TM)


12/22/2008 2:49:39 PM

JEFFERSON, N.C., Dec. 22 /PRNewswire/ -- Next Safety has developed a proprietary platform that delivers nicotine and a number of other drugs including albuterol and the components of Advair(TM), fluticasone propionate and salmeterol xinofoate, in air timed to the user's inhalation. Certain US patents for the chemical components of Advair(TM) expired September 2008.

Next Safety's platform has numerous advantages over current methods used for delivering these significant asthma medications. The benefits include the use of air instead of refrigerant-based propellants and the delivery of medication timed to the user's inhalation, unlike dry powder inhalation devices.

(http://tinyurl.com/68twd7)

NSI has decided to sell intellectual property and other related assets for the pulmonary delivery of certain asthma medications, utilizing its proprietary platform, in a competitive bidding process that includes a number of leading, global pharmaceutical companies.

According to Eric Hunter, CEO of Next Safety, "We are selling the assets related to the pulmonary delivery of albuterol, fluticasone and salmeterol in a bid process that ends February 12, 2009."

This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.

CONTACT: George Colvard, COO, georgecolvard@nextsafety.com, or Philip
Weaver, President, philipweaver@nextsafety.com, both of Next Safety

Web site: http://www.nextsafety.com/



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES